A rumor that pharmaceutical companies behind popular weight-loss and diabetes medications like Ozempic faced lawsuits ...

Viking Therapeutics' stock drops 40% despite strong Phase 2 weight-loss drug results. See here to know why I remain ultra ...

Pharmaceutical giant Eli Lilly said last week that it will raise the U.K. list price of its weight-loss treatment Mounjaro by ...

New pill orforglipron was associated with a significant reduction in body weight and better cholesterol, triglycerides and blood pressure.

Viking's key drug demonstrated excellent body weight reduction data in a phase 2 trial, but its safety and tolerability data ...

Discover potential risks for Novo Nordisk using Charlie Munger's inversion model. Explore market share, R&D, and why this ...

The move is likely part of the company’s goal to reduce costs as it faces increased competition in the GLP-1 space.

The UK list price of the weight loss drug could nearly triple, but which patients will bear the brunt of the internationally “aligned” cost? Kate Bowie reports In May the Trump administration demanded ...

A Shropshire GP has said many patients are worried about having to stop their weight loss journey as the cost of Mounjaro is ...

This is an audio transcript of the FT News Briefing podcast episode: ‘What to expect from Jay Powell’s Jackson Hole speech’ Sonja Hutson Good morning from the Financial Times. Today is Wednesday, ...

Why did Viking Therapeutics stock drop after its obesity drug trial update? Viking Therapeutics shares slumped sharply this week after the company’s latest obesity drug trial update failed to match ...